A recent investigation from KFF Health News about payments to members of an FDA panel evaluating an Abbott Laboratories cardiac device is raising eyebrows.
Key collaborators across the healthcare AI life cycle now have a common set of principles to which they can hold each other. And that means everyone from developers and researchers to providers, regulators and even patients.
CMS must ensure transparency, clarity and predictability by providing detailed guidance on comparator drug selection and the evaluation of evidence, according to a group of D.C.-based health policy researchers.
Bumping up hard against the reality of depleted data sources, three of AI’s top players have been acting like they’ve had no choice but to consider cutting corners.
Two-fifths of leaders at academic medical centers, 41%, see reducing average length of patient stay as far and away the No. 1 “most untapped” strategy to turn around falling operating margins.
A new study from researchers at Cedars-Sinai Medical Center should put minds at ease that the conservative management approach will not result in litigation when guidelines are followed.
Providers and payers disagree on a lot of things. But the camps are united in their appreciation of workers who have skills relevant to advancing GenAI in healthcare.